• Immunic is presenting new vidofludimus calcium data at MSToronto2026 in Toronto, running Oct. 21-23, 2026.
• Phase 2 CALLIPER extension findings showed sustained favorable disability trends with continued treatment; safety remained consistent with the double-blind period.
• Exploratory analyses linked reduced Epstein-Barr virus-specific immune signatures to improved cognitive performance, supporting further investigation.
• Preclinical findings suggested neuroprotective effects beyond DHODH inhibition, including improved neuronal survival dependent on Nurr1 activation.
• A Phase 3 progressive MS program is planned for later this year; relapsing MS trial results are expected by year-end 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immunic Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NY77183) on October 21, 2026, and is solely responsible for the information contained therein.